

Maidstone and Tunbridge Wells

NHS Trust

Ref: FOI/CAD/ID 4240

Please reply to:
FOI Administrator
Trust Management
Service Centre
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ

Email: mtw-tr.foiadmin@nhs.net

21 September 2017

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Biologics and Biosimilar prescribing.

Could you please provide me with the following numbers of patients treated in the last 12 months [latest 12 months possible] with the following drugs for the conditions listed below?

- *Psoriasis*
- *Hidradenitis Suppurativa*
- *Crohn's disease*
- *Ulcerative Colitis*

Please see the following completed table: Figures are for September 2016 – August 2017

Number of patients treated	Psoriasis	Hidradenitis Suppurativa	Crohn's disease	Ulcerative Colitis
TOTAL				
Abatacept [Orencia]	0	0	0	0
Adalimumab [Humira]	0	0	89	17
Apremilast [Otezla]	0	0	0	0
Baricitinib [Olumiant]	0	0	0	0
Certolizumab [Cimzia]	0	0	0	0
Etanercept [Enbrel]	0	0	0	0
Etanercept Biosimilar [Benepali or Erelzi]	0	0	0	0
Golimumab [Simponi]	0	0	0	0
Infliximab [Remicade], Biosimilar [Inflectra, Remsima or Flixabi]	0	0	119	25
Rituximab [Mabthera]	0	0	0	0
Rituximab Biosimilar [Rixathon or Truxima]	0	0	0	0

Secukinumab [Cosentyx]	0	0	0	0
Tocilizumab [Ro Actemra]	0	0	0	0
Tofacitinib [Xeljanz]	0	0	0	0
Ustekinumab [Stelara]	0	0	0	0
Vedolizumab [Entyvio]	0	0	13	19
Ixekizumab [Taltz]	0	0	0	0